D. Zelinger

发表

Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

M. Simoons, B. van Hout, L. Bowman, 1998, American heart journal.

Clinical Pathologic Alterations Associated with Subcutaneous Administration of Recombinant Human Interleukin-4 to Cynomolgus Monkeys

T. Barbolt, K. Gossett, J. Dean, 1993, Toxicologic pathology.

Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

M. Simoons, B. van Hout, L. Bowman, 1998, European Heart Journal.

Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohnʼs Disease: A Post-hoc Analysis of the ACCENT1 Trial: 1226

P. Rutgeerts, S. Vermeire, S. Hanauer, 2011 .

Subchronic Oral and Intravenous (iv) Safety Evaluation and Pharmacokinetics in Rats and Dogs of Ipazilide Fumarate (Win 54, 177-4), an Antiarrhythmic Agent

T. Barbolt, J. Dean, B. Mayes, 1992 .

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.

T. Schnitzer, M. Mayes, M. Weisman, 1995, Arthritis and rheumatism.

A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.

A. Keshavarzian, L. Mayer, F. Cominelli, 2007, Gastroenterology & hepatology.

Safety of readministration of abciximab; interim results of the ReoPro readministration registry (R3)

R. Jordan, M. Effron, J. Tcheng, 1998 .

Reduction of animal use with improved procedure for acute tolerance assessment.

H. Olson, J. Dean, Y. Greener, 1993, Regulatory toxicology and pharmacology : RTP.